The Revealing Impact of Dry Mouth

EVOXAC is indicated for the treatment of dry-mouth symptoms of Sjögren's syndrome.

• Cevimeline is contraindicated in patients with uncontrolled asthma, known hypersensitivity to the drug, and when miosis is undesirable, e.g., in acute iritis and narrow-angle (angle-closure) glaucoma
• Cevimeline can potentially alter cardiac conduction and heart rate and produce transient changes in hemodynamics. Cevimeline should be administered with caution and under close medical supervision to patients with a history of cardiac disease, controlled asthma, chronic bronchitis, or chronic obstructive pulmonary disease
• Cevimeline should be administered with caution to patients taking beta-adrenergic antagonists because of the possibility of conduction disturbances and to patients with a history of nephrolithiasis or cholelithiasis
• If a patient sweats excessively while taking cevimeline, dehydration may develop
• Caution should be advised while driving at night or performing hazardous activities in reduced lighting

• Safety and effectiveness in pediatric patients have not been established
• Cevimeline is metabolized by the P-450 isozymes CYP2D6 and CYp3A3/4. Thus, there may be potential for interaction between cevimeline and other compounds
• Special care should be exercised when cevimeline is taken by geriatric patients, considering the greater frequency of decreased hepatic, renal, or cardiac function
• The most frequently reported adverse events associated with the pharmacologic action of a muscarinic agonist (>10% incidence) in clinical trials of cevimeline were: excessive sweating, nausea, rhinitis, and diarrhea. Consult the full prescribing information for other adverse events